Literature DB >> 17631433

Ethics and stem cell therapeutics for cardiovascular disease.

Jeremy Sugarman1.   

Abstract

As research on stem cell therapeutics for the treatment of cardiovascular diseases in adults is being planned and conducted it is essential to address the ethical issues associated with it. The considerable attention that is currently focused on the ethical issues associated with stem cell research as well as the acute clinical situations sometimes encountered when treating cardiovascular disease, underscore the need for explicit attention to the ethical aspects of this research. In this article, I survey some of the key ethical considerations regarding research involving stem cell therapeutics for cardiovascular diseases including: (1) the standard ethical considerations for translational and clinical research and mechanisms of ethical oversight of them; (2) additional oversight related to stem cell research; (3) considerations for obtaining informed consent for this research and in selecting individual human subjects to participate in it; (4) concerns related to justice that may manifest themselves with respect to which research endeavors move forward and (5) conflicts of interest in research and their potential relationship to research integrity.

Entities:  

Mesh:

Year:  2007        PMID: 17631433     DOI: 10.1016/j.pcad.2007.02.003

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  2 in total

Review 1.  Do we still need human embryonic stem cells for stem cell-based therapies? Epistemic and ethical aspects.

Authors:  Kristina Hug; Göran Hermerén
Journal:  Stem Cell Rev Rep       Date:  2011-11       Impact factor: 5.739

2.  Longitudinal study of informed consent in innovative therapy research: experience and provisional recommendations from a multicenter trial of intracerebral grafting.

Authors:  Laurent Cleret de Langavant; Sophie Sudraud; Christophe Verny; Pierre Krystkowiak; Clémence Simonin; Philippe Damier; Jean-François Demonet; Frédéric Supiot; Amandine Rialland; David Schmitz; Patrick Maison; Katia Youssov; Anne-Catherine Bachoud-Lévi
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.